{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Specimen+%231&page=32", "query": { "intervention": "Specimen #1", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 2698, "total_pages": 270, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Specimen+%231&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Specimen+%231&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T17:28:39.370Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04799275", "title": "Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Ann Arbor Stage III Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma", "Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Grade 3b Follicular Lymphoma", "HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Intravascular Large B-Cell Lymphoma", "Lymphoplasmacytic Lymphoma", "Nodular Lymphocyte Predominant B-Cell Lymphoma", "Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Oral Azacitidine", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Rituximab and Hyaluronidase Human", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "75 Years", "maximum_age": null, "sex": "ALL", "summary": "75 Years and older" }, "enrollment_count": 422, "start_date": "2021-05-20", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-16T17:28:39.370Z", "location_count": 176, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 136 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04799275" }, { "nct_id": "NCT03067181", "title": "Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Childhood Extracranial Germ Cell Tumor", "Extragonadal Embryonal Carcinoma", "Germ Cell Tumor", "Malignant Germ Cell Tumor", "Malignant Ovarian Teratoma", "Stage I Ovarian Choriocarcinoma", "Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7", "Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7", "Stage I Testicular Choriocarcinoma AJCC v6 and v7", "Stage I Testicular Embryonal Carcinoma AJCC v6 and v7", "Stage I Testicular Seminoma AJCC v6 and v7", "Stage I Testicular Yolk Sac Tumor AJCC v6 and v7", "Stage II Ovarian Choriocarcinoma", "Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7", "Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7", "Stage II Testicular Choriocarcinoma AJCC v6 and v7", "Stage II Testicular Embryonal Carcinoma AJCC v6 and v7", "Stage II Testicular Yolk Sac Tumor AJCC v6 and v7", "Stage III Ovarian Choriocarcinoma", "Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7", "Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7", "Stage III Testicular Choriocarcinoma AJCC v6 and v7", "Stage III Testicular Embryonal Carcinoma AJCC v6 and v7", "Stage III Testicular Yolk Sac Tumor AJCC v6 and v7", "Stage IV Ovarian Choriocarcinoma", "Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7", "Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7", "Testicular Mixed Choriocarcinoma and Embryonal Carcinoma", "Testicular Mixed Choriocarcinoma and Teratoma", "Testicular Mixed Choriocarcinoma and Yolk Sac Tumor" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bleomycin Sulfate", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pulmonary Function Test", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1780, "start_date": "2017-05-25", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-16T17:28:39.370Z", "location_count": 566, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 338 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03067181" }, { "nct_id": "NCT07869381", "title": "Trial Comparing CPDMA Versus Standard Breadloafing in WLE Specimens of Stage 1-II Cutaneous Melanoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cutaneous Melanoma, Stage II", "Cutaneous Melanoma", "Acral Melanoma" ], "interventions": [ { "name": "Wide Local Excision", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 282, "start_date": "2026-12-24", "completion_date": "2031-12-24", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-16T17:28:39.370Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT07869381" }, { "nct_id": "NCT07863765", "title": "Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Differentiated Thyroid Gland Carcinoma", "Metastatic NUT Carcinoma", "Metastatic Thyroid Gland Anaplastic Carcinoma", "Metastatic Thyroid Gland Medullary Carcinoma", "Refractory Differentiated Thyroid Gland Carcinoma", "Stage III Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage III Thyroid Gland Medullary Carcinoma AJCC v8", "Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage IV Thyroid Gland Medullary Carcinoma AJCC v8", "Unresectable Differentiated Thyroid Gland Carcinoma", "Unresectable NUT Carcinoma", "Unresectable Thyroid Gland Anaplastic Carcinoma", "Unresectable Thyroid Gland Medullary Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Enfortumab Vedotin", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2027-05-05", "completion_date": "2031-05-05", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-16T17:28:39.370Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07863765" }, { "nct_id": "NCT04323202", "title": "Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Basal Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Tissue collection", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2020-08-04", "completion_date": "2025-06-25", "has_results": false, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-10-16T17:28:39.370Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04323202" }, { "nct_id": "NCT00579566", "title": "Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "Specimen protocol", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 3000, "start_date": "2002-06", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-16T17:28:39.370Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00579566" }, { "nct_id": "NCT05947500", "title": "Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8", "Locally Advanced Merkel Cell Carcinoma", "Metastatic Merkel Cell Carcinoma", "Refractory Merkel Cell Carcinoma", "Unresectable Merkel Cell Carcinoma" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Tuvusertib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2024-05-21", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-16T17:28:39.370Z", "location_count": 50, "location_summary": "Irvine, California • La Jolla, California • Los Angeles, California + 39 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05947500" }, { "nct_id": "NCT02937545", "title": "Delivery of Pharmacogenetic Testing in a Community Pharmacy Setting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pharmacogenetics" ], "interventions": [ { "name": "Medication Therapy Management", "type": "OTHER" }, { "name": "Pharmacogenetic testing", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 190, "start_date": "2017-02-22", "completion_date": "2019-09-10", "has_results": true, "last_update_posted_date": "2021-06-03", "last_synced_at": "2026-10-16T17:28:39.370Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02937545" }, { "nct_id": "NCT05638295", "title": "Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Panitumumab", "type": "BIOLOGICAL" }, { "name": "Sotorasib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2024-08-01", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-16T17:28:39.370Z", "location_count": 180, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 135 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05638295" }, { "nct_id": "NCT07200830", "title": "Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Adenocarcinoma", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Lutetium Lu 177 Vipivotide Tetraxetan", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Patient Monitoring", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "PSMA PET Scan", "type": "PROCEDURE" }, { "name": "MRI", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1524, "start_date": "2026-03-31", "completion_date": "2034-09-09", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-16T17:28:39.370Z", "location_count": 138, "location_summary": "Anchorage, Alaska • Bakersfield, California • Irvine, California + 114 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Bakersfield", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07200830" } ] }